Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Michael Young who wrote (3614)	4/27/2001 4:11:01 PM
From: RCMac	Read Replies (1) \| Respond to of 52153

>> the annual sales for Zyprexa? << About $2 billion in 2000, about $625 million 1Q01 (i.e., $2.5B annualized). Up from $700M in 1998, about $1.2B in 1999, following launch in 1996. This is from memory, from somewhere in connection with TTP, one of my larger holdings (whose Zomaril, now in phase III with Novartis, will compete in the same anti-Schizophrenic market, and which also appears to avoid Zyprexa's weight-gain side effect), but I'm pretty sure the Zyprexa numbers are right. --RCM